首页> 外文期刊>Journal of biomaterials applications >Evaluation by bone scintigraphy of osteogenic activity of commercial bioceramics (porous beta-TCP and HAp particles) subcutaneously implanted in rats.
【24h】

Evaluation by bone scintigraphy of osteogenic activity of commercial bioceramics (porous beta-TCP and HAp particles) subcutaneously implanted in rats.

机译:通过骨闪烁显像技术评估皮下植入大鼠体内的商用生物陶瓷(多孔β-TCP和HAp颗粒)的成骨活性。

获取原文
获取原文并翻译 | 示例
           

摘要

Osteogenic potential of biomaterials used in bone regenerative therapy has been mainly examined in an animal-implantation study. We have here evaluated the applicability of bone scintigraphy in imaging ectopic bone formation, especially its initial phase, by beta-tricalcium phosphate (beta-TCP) particles that were implanted in rat dorsal subcutaneous tissues. In implanted osteogenic osteosarcoma cells used as a positive control, osteoid formation was found by histological examination and bone scintigraphy using (99m)Tc- hydroxymethyl diphosphonate (HMDP) at 2 and 3 weeks post-implantation, respectively, while the microfocuscomputed tomography (muCT) system required further mineralization, which occurred at 4 weeks. Implantation of beta-TCP particles alone induced only faint biomineralization inside the particles, which could be microscopically detected by calcein chelation at 2 weeks post-implantation, but not by other histological examinations (e.g., HE staining) or muCT. However, the bone scintigraphy successfully detected this microscopic change at 1 week. Implanted hydroxyapatite (HAp) particles alone used as a negative control did not induce mineralization at microscopic levels, and therefore nothing was detected by either calcein chelation or bone scintigraphy. In conclusion, the bone scintigraphic methodology, although exhibiting less quantitation and resolution, would be applicable as a non-invasive, highly sensitive methodology in detecting the initial, microscopic changes associated with mineralization.
机译:在一项动物植入研究中,主要研究了用于骨再生治疗的生物材料的成骨潜能。我们在这里评估了骨闪烁显像术在异位骨形成成像中的适用性,特别是通过植入大鼠背侧皮下组织中的β-磷酸三钙(β-TCP)颗粒对异位骨形成进行成像的适用性。在植入的成骨性骨肉瘤细胞中用作阳性对照,分别在植入后2周和3周通过组织学检查和骨闪烁显像(99m)Tc-羟甲基二膦酸酯(HMDP)发现类骨形成,而微聚焦计算机断层扫描(muCT)系统需要进一步矿化,发生在4周。单独植入β-TCP颗粒只会引起颗粒内部微弱的生物矿化,可以在植入后2周通过钙黄绿素螯合显微镜检测到,但不能通过其他组织学检查(例如HE染色)或muCT显微镜检测到。但是,骨闪烁显像术在1周时成功检测到了这种微观变化。单独用作阴性对照的植入羟基磷灰石(HAp)颗粒在微观水平上不会诱导矿化作用,因此钙黄绿素螯合法或骨闪烁显像法都检测不到。总之,尽管骨闪烁显像法定量和分离度较低,但仍可作为一种非侵入性,高度灵敏的方法来检测与矿化有关的初始微观变化。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号